Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

View original at finance.yahoo.com
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference Legend Biotech USA Inc…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Patients treated earlier, after one or two prior lines of therapy, exhibited greater immune fitness and a more immunocompetent tumor microenvironment, potential biological indicators of longer progression-free survival

    80% confidence

  • Targeting multiple investigational new drug (IND) filings for oncology and autoimmune indications starting in second half 2026

    80% confidence

  • The Company believes cash and cash equivalents, and time deposits of approximately $1.0 billion as of September 30, 2025, will provide financial runway beyond 2026

    80% confidence

  • Triple-class-exposed patients treated with three prior lines of therapy from the CARTITUDE-1 and CARTITUDE-4 trials achieved a median progression-free survival of 50.4 months following a single infusion of CARVYKTI

    80% confidence

  • CARVYKTI cemented its status as the undisputed leader in multiple myeloma CAR-T cell therapy, with its continued record-breaking performance culminating in the achievement of more than 10,000 patients treated earlier this year

    80% confidence

  • First-in-human data for in vivo dual CD20/CD19 therapy expected starting in the second half of 2026

    80% confidence

  • Legend Biotech is poised for transformative growth in 2026, as we work to achieve profitability this year by driving global adoption of CARVYKTI

    80% confidence

  • Expect company-wide operating profit in 2026

    80% confidence

  • The latest NCCN guidelines recommend talquetamab as a bridging therapy before CAR-T treatment for people with relapsed/refractory multiple myeloma to help keep patients eligible for CARVYKTI and improve outcomes

    80% confidence

  • We're also committed to leveraging our proven CAR-T development platform to frontline multiple myeloma and promising new in vivo and allogeneic opportunities to extend our leadership in cell therapy innovation

    80% confidence

  • Anticipate CARVYKTI franchise FY 2025 profitability

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com